UHE-103 Cream for Tinea Pedis

Phase-Based Progress Estimates
Tinea Pedis+6 More
UHE-103 Cream - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new cream for treating skin fungal infections. The main goals are to see if it is safe and tolerated by people, and how it is absorbed into the body.

Eligible Conditions
  • Tinea Pedis
  • Tinea Cruris

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: Day 16

Day 16
Adverse Events (AEs)
Day 15
AUC (0-12 hours)
Day 16
Local Skin Reactions (LSRs)

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Naftin (naftifine hydrochloride) Cream, 2%
1 of 2
UHE-103 Cream
1 of 2
Active Control
Experimental Treatment

40 Total Participants · 2 Treatment Groups

Primary Treatment: UHE-103 Cream · No Placebo Group · Phase 1

UHE-103 Cream
Experimental Group · 1 Intervention: UHE-103 Cream · Intervention Types: Drug
Naftin (naftifine hydrochloride) Cream, 2%
ActiveComparator Group · 1 Intervention: Naftin (naftifine hydrochloride) Cream · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: day 16

Who is running the clinical trial?

Therapeutics, Inc.Lead Sponsor
27 Previous Clinical Trials
3,756 Total Patients Enrolled
1 Trials studying Tinea Pedis
240 Patients Enrolled for Tinea Pedis
Tony AndrasfayStudy DirectorTherapeutics Inc. (CRO)
5 Previous Clinical Trials
488 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a male or non-pregnant female 18 years of age or older.
You have at least moderate scaling on at least 1 foot at Visit 1/Screening.
You have a clinical diagnosis of interdigital tinea pedis with at least moderate scaling on at least 1 foot (without moccasin-type tinea pedis) and tinea cruris at Visit 1/Screening.
You are willing and able to apply the test article(s) as directed, comply with study instructions, and commit to all follow-up visits for the duration of the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 6th, 2021

Last Reviewed: October 19th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.